JP2012524090A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524090A5
JP2012524090A5 JP2012506089A JP2012506089A JP2012524090A5 JP 2012524090 A5 JP2012524090 A5 JP 2012524090A5 JP 2012506089 A JP2012506089 A JP 2012506089A JP 2012506089 A JP2012506089 A JP 2012506089A JP 2012524090 A5 JP2012524090 A5 JP 2012524090A5
Authority
JP
Japan
Prior art keywords
composition
trifluoropentanamide
oxadiazol
chlorophenyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012506089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030679 external-priority patent/WO2010120662A2/en
Publication of JP2012524090A publication Critical patent/JP2012524090A/ja
Publication of JP2012524090A5 publication Critical patent/JP2012524090A5/ja
Pending legal-status Critical Current

Links

JP2012506089A 2009-04-14 2010-04-12 アモルファスα−(N−スルホンアミド)アセトアミド化合物の生物学的に利用可能な組成物 Pending JP2012524090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16906609P 2009-04-14 2009-04-14
US61/169,066 2009-04-14
PCT/US2010/030679 WO2010120662A2 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (2)

Publication Number Publication Date
JP2012524090A JP2012524090A (ja) 2012-10-11
JP2012524090A5 true JP2012524090A5 (enExample) 2013-03-28

Family

ID=42664672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012506089A Pending JP2012524090A (ja) 2009-04-14 2010-04-12 アモルファスα−(N−スルホンアミド)アセトアミド化合物の生物学的に利用可能な組成物

Country Status (21)

Country Link
US (1) US20100261768A1 (enExample)
EP (1) EP2419086B1 (enExample)
JP (1) JP2012524090A (enExample)
KR (1) KR20120027142A (enExample)
CN (1) CN102387788B (enExample)
AR (1) AR076306A1 (enExample)
AU (1) AU2010236701A1 (enExample)
BR (1) BRPI1012523A2 (enExample)
CA (1) CA2758709A1 (enExample)
DK (1) DK2419086T3 (enExample)
EA (1) EA201171207A1 (enExample)
ES (1) ES2426403T3 (enExample)
HR (1) HRP20130807T1 (enExample)
MX (1) MX2011010513A (enExample)
NZ (1) NZ595411A (enExample)
PL (1) PL2419086T3 (enExample)
PT (1) PT2419086E (enExample)
SI (1) SI2419086T1 (enExample)
SM (1) SMT201300106B (enExample)
TW (1) TW201043269A (enExample)
WO (1) WO2010120662A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AR087277A1 (es) * 2011-07-21 2014-03-12 Bristol Myers Squibb Co Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 4環性化合物的非晶質體的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999007A (en) * 1975-10-09 1976-12-21 Carl Joseph Crane Aircraft visual approach/landing reproducer device and system
US5136301A (en) * 1989-08-30 1992-08-04 Rockwell International Corporation Primary flight display system having a vertical linear altimeter
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
DE69606804T2 (de) * 1995-06-20 2000-06-15 Honeywell, Inc. Integriertes System zur Grundkollisionsvermeidung
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
US6233522B1 (en) * 1998-07-06 2001-05-15 Alliedsignal Inc. Aircraft position validation using radar and digital terrain elevation database
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6570531B1 (en) * 2000-04-27 2003-05-27 Rockwell Collins, Inc. Satellite navigation receiver designed for compatibility with aircraft automatic landing systems
US6483454B1 (en) * 2000-11-28 2002-11-19 Bae Systems Aerospace Inc. Close formation aircraft collision avoidance
CN1289469C (zh) * 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α-(N-磺酰氨基)乙酰胺衍生物作为β-淀粉样蛋白抑制剂
CN101274926A (zh) * 2003-03-31 2008-10-01 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
FR2870605B1 (fr) * 2004-05-18 2010-10-08 Airbus France Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude
FR2880456B1 (fr) * 2005-01-03 2007-02-23 Airbus France Sas Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef
FR2886439B1 (fr) * 2005-05-24 2010-11-05 Eurocopter France Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude
CN101384250A (zh) * 2005-11-09 2009-03-11 诺瓦提斯公司 利用临时增塑剂制备药物组合物的方法
FR2897448B1 (fr) * 2006-02-14 2008-03-14 Airbus France Sas Procede et systeme d'aide au pilotage d'un aeronef.
JP2009528281A (ja) * 2006-02-17 2009-08-06 ワイス スルホンアミド置換アルコールおよびその中間体の調製方法
TW200732295A (en) * 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US20070218012A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
FR2911988B1 (fr) * 2007-01-26 2016-03-25 Airbus France Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Similar Documents

Publication Publication Date Title
JP2012524090A5 (enExample)
IL214942A (en) N, n– Dimethyl-5– (2-methyl-6 - ((5-methylpyrazine-2-yl) carbamole) Benzoporen-4-Iloxy) Pyrimidine-2-carboxamide and the salts common in its pharmacies, pharmaceuticals containing them and their uses in the preparation of drugs
NZ605232A (en) Formulations of rifaximin and uses thereof
IL216667A (en) Cyclopropane-Carboxylic Acid {5- (4- (1,1- Dioxo-1-Thiomorpholine-4-Illmethyl) -phenyl) - [4,2,1] Triazolo (5,1- a) Pyridine-2-Ill} Affluent, pharmaceutical preparations containing it and its uses
IL184712A (en) History of pyrzulo-pyrimidine, process of preparation, medicinal preparations containing them and use of pharmaceutical preparations
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
TW200831103A (en) Crystalline forms of pemetrexed diacid and processes for the preparation thereof
NZ599031A (en) A dosage form containing two or more active pharmaceutical ingredients in different physical forms
NO20073722L (no) Farmasoystiske sammensetniger omfattende bendamustin
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
JP2014167026A5 (enExample)
JP2013529637A5 (enExample)
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
JP2017521469A5 (enExample)
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
WO2014093583A3 (en) Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
MX2011010514A (es) Composiciones de capsulas biodisponibles de compuesto amorfo alfa-(n-sulfonamido)acetamida.
WO2014118808A3 (en) Ticagrelor solid dispersion
IL213983A (en) Derivatives of pyridazinone that are converted into heteroaryl, their process, their pharmaceutical preparations and their use in the preparation of drugs
SMT201300106B (it) Composizioni biodisponibili di composto alfa-(N-sulfonammido)acetammide amorfo
JP2012502156A5 (enExample)
WO2009122187A3 (en) Pharmaceutical composition
WO2010020799A3 (en) Compositions for the treatment of neoplastic diseases
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen